| Jennifer Jozwiak, MA | |
|
1459 Ridge St, Ste 2, Naples, FL 34103-4211 | |
| (239) 262-6668 | |
| (239) 262-0017 |
| Full Name | Jennifer Jozwiak |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 34 Years |
| Location | 1459 Ridge St, Naples, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427215383 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AY745 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Collier Otolaryngology - Head And Neck Surgery Pa | 2466467170 | 3 |
News Archive
The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.
Over the next 18 months, between one quarter and one half of Americans who get insurance coverage through their employers will pay more of their doctor bills themselves as companies roll out healthcare plans with higher deductibles, benefits consultants say.
A new approach may be able to reduce by more than half the time it takes health officials to identify Salmonella strains, according to researchers in Penn State's College of Agricultural Sciences.
Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.
› Verified 6 days ago
| Provider Name | Collier Otolaryngology - Head And Neck Surgery Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1851580740 PECOS PAC ID: 2466467170 Enrollment ID: O20060217000102 |
News Archive
The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.
Over the next 18 months, between one quarter and one half of Americans who get insurance coverage through their employers will pay more of their doctor bills themselves as companies roll out healthcare plans with higher deductibles, benefits consultants say.
A new approach may be able to reduce by more than half the time it takes health officials to identify Salmonella strains, according to researchers in Penn State's College of Agricultural Sciences.
Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Jozwiak, MA 1879 Veterans Park Drive, Ste. 1201, Naples, FL 34109-0492 Ph: (239) 592-9666 | Jennifer Jozwiak, MA 1459 Ridge St, Ste 2, Naples, FL 34103-4211 Ph: (239) 262-6668 |
News Archive
The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.
Over the next 18 months, between one quarter and one half of Americans who get insurance coverage through their employers will pay more of their doctor bills themselves as companies roll out healthcare plans with higher deductibles, benefits consultants say.
A new approach may be able to reduce by more than half the time it takes health officials to identify Salmonella strains, according to researchers in Penn State's College of Agricultural Sciences.
Calibr, the drug development division of Scripps Research, announced today that the U.S. Food and Drug Administration has cleared its investigational new drug application for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer.
› Verified 6 days ago
Ms. Christine Noelle Peacock, M.A., CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1250 Tamiami Trl N Ste 110, Naples, FL 34102 Phone: 239-434-2434 | |
Dr. Kaitlin Doidge, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2332 Pine Ridge Rd, Naples, FL 34109 Phone: 239-434-7000 | |
Dr. Timothy John Roupas, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1000 Tamiami Trl N, 403, Naples, FL 34102 Phone: 239-434-0086 Fax: 239-434-9029 | |
Dr. Linda K Burkart, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 400 8th St N, Naples, FL 34102 Phone: 239-261-7722 Fax: 239-261-8491 | |
Dr. Deborah J Olsen, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 6101 Pine Ridge Rd, Naples, FL 34119 Phone: 239-348-4000 Fax: 239-348-4001 | |
Sheryl L Stratton Brogdon, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 11181 Health Park Blvd Ste 3000, Naples, FL 34110 Phone: 239-430-5550 Fax: 239-430-5559 | |
Rachel Marie Spencer, AU.D Audiologist Medicare: Not Enrolled in Medicare Practice Location: 971 Michigan Ave, Naples, FL 34103 Phone: 239-593-5327 |